Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer

Phase 1Active Not RecruitingNCT04943536

Alessa Therapeutics Inc.20 enrolled

Overview

This study will be undertaken to evaluate the feasibility of replacing systemic Androgen Deprivation Therapy (ADT) with targeted local delivery of an anti-androgen agent alone in patients in whom ADT + radiation therapy is indicated for the treatment of localized prostate cancer.

This study is a prospective, single-center, single-arm feasibility study. Up to 20 participants will be recruited to assess the safety and patient tolerance of Biolen for the localized delivery of bicalutamide into the prostate when delivered with radiotherapy. At baseline, patients will undergo multiparametric MRI of the prostate. Study participants will have placement of the drug eluting Biolen implants. At the 8 week timepoint, participants will undergo repeat multiparametric MRI. Participants will receive standard of care radiation therapy on weeks 9-11 and will be followed through 2 years post radiation. A third and fourth multiparametric MRI will be performed at 6 and 24 months after completion of radiation. Clinical labs and correlative sample collection and patient quality of life questionnaires will be administered at follow-up visits. Following completion of follow-up or removal from protocol, patients may be offered enrollment on long-term follow up protocols.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostate Adenocarcinoma

Interventions

bicalutamideDRUG

localized anti-androgen therapy

Stereotactic body radiation therapyRADIATION

localized radiation therapy

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with biopsy proven localized prostate cancer in whom prostate radiation and ADT is appropriate therapy (such as Intermediate Risk localized prostate cancer) * Patients must have at least 1 MRI detected; biopsy proven prostate cancer. * Patients diagnosed as one of the following: 1. National Comprehensive Cancer Network (NCCN) intermediate risk prostate cancer, OR 2. NCCN high risk prostate cancer due to Gleason Grade 4 or 5 AND refuses to receive systemic ADT, OR 3. NCCN high risk prostate cancer due to Prostate Specific Antigen (PSA) \> 20 AND refuses to receive systemic ADT. * Age \>18 years. Exclusion Criteria: * NCCN high risk patients eligible for treatment with systemic ADT who do not refuse systemic ADT. * Patients receiving prior radiotherapy or surgery for prostate cancer. * Patients receiving prior or ongoing ADT. * Study participant unwilling or unable to undergo MRI, including patients with contra-indications to MRI, such as cardiac pacemakers, non-compatible intracranial vascular clips, etc. * Use of 5 alpha reductase inhibitors (e.g. Finasteride or Dutasteride) within 3 months of screening or total use within the last two years prior to screening of \> 3 months. * Prostate volume more than 80 cc at prior MRI imaging. * International Prostate Symptom Score ≥ 20.

Locations (1)

National Cancer Institute

Bethesda, Maryland, United States

Outcomes

Primary Outcomes

Feasibility of replacing systemic androgen tx with targeted local delivery

Ability to successfully implant the prostate with Biolen and a lack of implant toxicity that interferes with the capacity to complete intended radiation therapy.

Time frame: 27 months

Secondary Outcomes

Adverse Events

toxicity of localized delivery of bicalutamide

Time frame: through 27 months

MRI changes

prostate and tumor volume changes

Time frame: baseline versus 8 weeks post biolen implantation and 6 months post RT

Biochemical progression free survival

rate of biochemical progression free survival

Time frame: 24 months post RT

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.